EU Horizon 2020 – MISTRAL
AELIX is an active partner in the international Consortium of the MISTRAL project, funded within the framework of European Union’s Horizon 2020 programme with a Grant Agreement number 847943.
The MISTRAL project is exploring the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies. In addition, the creation of a publicly accessible database will aid inpatient screening and stratification. A cloud-based tool will also facilitate microbiome interpretation for reseach and clinical purposes.
2018: ACCIÓ – Nuclis program
AELIX has received a grant for the project “Development of a therapeutic vaccine for the treatment of the HIV infection” through the Nuclis program of Agencia per a la Competitivitat de l’Empresa, ACCIÓ, that stimulates industrial research and experimental development activities framed in RIS3CAT and PO FEDER Catalunya 2014-2020 financing programs.
The details of the project can be read at the below link: https://www.aelixtherapeutics.com/wp-content/uploads/2022/06/220602_texto-publicidad.pdf
2017: RETOS-COLABORACIÓN Program – NUVATERA
AELIX Therapeutics has been awarded a grant by the Ministry of Science, Innovation and Universities (Ministerio de Ciencia, Innovación y Universidades) through the 2017 RETOS-COLABORACIÓN call of the National Programme for Research, Development, and Innovation Addressing Society Challenges—within the framework of the National Plan for Scientific and Technological Research and Innovation.
AELIX Therapeutics is leading the consortium composed by Institut de Recerca de la Sida (IrsiCaixa) and Fundació Lluita Contra la Sida (FLS).
The project, “NUVATERA – Desarrollo de una nueva vacuna terapéutica contra el VIH” (Development of a novel therapeutic vaccine against HIV), with file number NUVATERA (RTC-2017-6473-1), is focused on the clinical development necessary to test the safety and efficacy of the HTI strategy as a therapeutic vaccine against HIV in humans, and to be able to advance to the following phase II clinical trials.
Aelix Therapeutics is supported by Spanish Government (Ministerio de Ciencia, Innovación y Universidades), Agencia Estatal de Investigación and FEDER Funds
2017: EIT Health
AELIX has received 50.000€ as non-refundable funding from EIT Health for its project “A EUROPEAN CURE FOR HIV INFECTION”.
The project is based on developing a therapeutic vaccine to be administered to HIV-infected people with the goal of controlling the HIV infection without the need of taking further antiretroviral drugs. The aim of the project is that the treated people will live longer and healthier lives.
2017: NEOTEC – CDTI
AELIX Therapeutics was awarded a NEOTEC grant by Centre for Industrial Technological Development (CDTI), the entity of Spanish Ministry of Economy, Industry and Competitiveness, for the biannual project “Desarrollo Clínico Inmunógeno HTI” (SNEO-20171166).
The grant of 212.500€ financed the activity related to developing a new therapeutic vaccine for HIV infection, from late preclinical stages to clinical proof-of-concept studies. Specifically, the grant has supported the development of the HIVACAT T-Cell immunogen in a Chimpanzee Adenovirus vector to induce a strong immune response that can lead to a functional cure in people living with HIV infection.
2017: FUNDACIÓ SUÑOL
The Fundació Suñol has contributed to the development of the HTI-based vaccine through the support it has provided to IrsiCaixa – Institut de Recerca de la Sida and the HIVACAT consortium’.